CREB3L4 over-expression dramatically reduced the HCC cell chemosensitivity to sorafenib, while CREB3L4 silencing significantly increased the chemosensitivity of HCC cells to sorafenib (Figures 5A–5D). The gene discussed is CREB3L4; the disease is hepatocellular carcinoma.